Why BV Keeps Coming Back: The Biofilm Problem Antibiotics Can't Solve

If you have dealt with bacterial vaginosis more than once, you already know the pattern. Antibiotics work. Within a week, the symptoms are gone. You feel normal again.

Then, somewhere between three and eight weeks later, you notice it again. The smell. The discharge. The low-grade feeling that something is off. You go back to the doctor. They prescribe the same antibiotic. You take it. It works. Then it comes back.

Between 20% and 70% of women who are treated for BV will experience a recurrence within 1 to 6 months. That is not a typo. In some populations, the recurrence rate is closer to three in four women within a year.

What Your Doctor Probably Told You

The standard explanation for BV recurrence sounds reasonable on the surface. BV is caused by an overgrowth of anaerobic bacteria, mainly Gardnerella vaginalis. Antibiotics like metronidazole and clindamycin kill those bacteria. But they also kill the protective Lactobacillus strains your vaginal microbiome depends on.

Without enough Lactobacillus to hold the acidic environment together, the opportunistic bacteria repopulate quickly. This is why BV keeps coming back, or so the traditional explanation goes.

But although this explanation is partly true, it misses a crucial layer. New research published in 2025 reveals something that changes the picture significantly. There are two additional mechanisms at work, and they explain why recurrence is so persistent even when women do everything right.

The Fortress You Cannot See

Picture this. A colony of Gardnerella vaginalis bacteria settles on the vaginal wall. At first, they are floating freely, called planktonic bacteria, and antibiotics can reach them and kill them without much trouble.

But within hours, something changes. The bacteria start secreting a sticky, sugar-based matrix. They use this matrix to anchor themselves to the vaginal epithelium and to each other. Layer by layer, they build a dense, protective structure.

This is a biofilm. And it is not just a wall. It is an active defense system.

In other words, when you take metronidazole, it kills the free-floating bacteria. You feel better. But the biofilm community embedded in the vaginal wall survives. The moment antibiotic levels drop, those bacteria seed right back out.

This is the core of the recurrence problem. Not hygiene. Not your partner. Not luck. A biofilm.

Your Own Microbiome Is Working Against the Treatment

But that is not all. In 2025, a landmark paper published in npj Biofilms and Microbiomes introduced a concept called vaginal pharmacomicrobiomics. And what it found is unsettling.

The study, titled "Vaginal pharmacomicrobiomics modulates risk of persistent and recurrent bacterial vaginosis," found that the composition of your vaginal microbiome directly affects how well antibiotics work. Specifically, certain bacteria in a dysbiotic vaginal environment can metabolize antibiotic compounds before they ever reach the biofilm.

Think about what this means. You swallow metronidazole. It gets absorbed into the bloodstream, diffuses into vaginal tissue, and starts building up at the infection site. But before it can penetrate the biofilm, some of the bacteria in the surrounding microbiome chemically break it down. The antibiotic is degraded on its way to the target.

You see, when a woman already has BV, her vaginal microbiome is heavily dysbiotic. The protective Lactobacillus strains are depleted. In their place are high concentrations of anaerobes like Prevotella, Mobiluncus, and Gardnerella itself. Some of these organisms produce enzymes that inactivate nitroimidazole drugs like metronidazole.

The result is that the women who need antibiotics to work the most are the same women whose microbiomes are most likely to neutralize those antibiotics. The infection creates the very conditions that allow it to survive treatment.

This was not hypothetical. The 2025 study showed measurable differences in antibiotic efficacy based on microbiome composition at the time of treatment. Women with certain microbial profiles had significantly higher recurrence rates, regardless of antibiotic adherence.

What Can Actually Break Down the Biofilm

In October 2025, researchers published a comprehensive review in Microorganisms (MDPI) titled "Natural Molecules, Nutraceuticals, and Engineered Nanosystems: A Comprehensive Strategy for Combating Gardnerella vaginalis-Induced BV."

The review mapped out the current state of research on biofilm disruption. And the picture it paints is more hopeful than the antibiotic track record might suggest.

The issue with standard antibiotics is that they are designed to kill actively dividing bacteria. Biofilm bacteria are largely dormant. They are not dividing fast, which means the drugs that target cell division have limited reach inside the biofilm.

Researchers are now investigating molecules that can dissolve or destabilize the biofilm matrix itself, independent of killing the bacteria inside it. Several natural compounds show real promise in preclinical work.

None of these are ready to replace antibiotics entirely. But the research framing has shifted. The question is no longer just "which antibiotic kills BV bacteria." It is "what combination of approaches can disrupt the biofilm, kill the bacteria inside it, and prevent reformation."

The Probiotic Approach Showing Real Promise

Remember earlier, when we talked about how Lactobacillus strains can suppress biofilm formation? This is where probiotics enter the recurrence conversation in a meaningful way.

In November 2025, a randomized, double-blind controlled pilot study was published in Communications Medicine (Nature portfolio, DOI: 10.1038/s43856-025-01236-4). The study tested vaginal-spray delivered Bacillus spore probiotics as a treatment and recurrence prevention strategy for BV.

Bacillus spore-forming bacteria are interesting because they survive in conditions that would destroy most Lactobacillus strains. They can persist in acidic or antibiotic-heavy environments and then germinate once conditions stabilize. In the gut, this is well established. In the vaginal tract, it is newer territory.

The results showed promise for reducing recurrence rates compared to placebo. The researchers noted that Bacillus spore probiotics appeared to interfere with the conditions that allow Gardnerella biofilm to re-establish after antibiotic treatment.

Does this mean Bacillus spore probiotics are the answer? Well, yes and no. This was a pilot study. The sample sizes were small. Larger randomized trials are needed before this becomes a clinical standard. But the mechanism makes sense, the study design was solid, and the results were in the right direction.

For more on the evidence behind vaginal probiotics broadly, including which strains have the strongest track record, see our Vaginal Probiotics Guide.

The Gut-Vaginal Link You Might Be Missing

One underappreciated piece of the recurrence puzzle is the gut-vaginal axis. The composition of your gut microbiome influences the bacteria that colonize vaginal tissue. When gut Lactobacillus populations are low, vaginal Lactobacillus populations tend to follow.

Antibiotics hit both. A course of metronidazole does not stay in one place. It disrupts gut flora alongside vaginal flora, which can slow the recovery of protective bacteria at both sites.

This creates a broader systemic vulnerability. Not just in the vaginal tract, but in the hormonal and immune pathways that depend on a healthy gut microbiome. For context on how gut bacteria affect estrogen metabolism specifically, the estrobolome research is worth understanding alongside this.

For a deeper look at the gut-vaginal connection and what it means practically, our guide on the gut-vaginal axis covers the mechanism in detail.

What This Means If You Keep Getting BV

This research is not just academically interesting. It reframes the entire problem in a way that should change how you approach treatment.

Antibiotics alone are not solving recurrent BV because they are addressing the planktonic bacteria while leaving the biofilm intact. They are fighting a battle on the wrong terrain. And in some women, the microbiome itself is degrading the antibiotics before they even get a chance to work.

This is not a personal failing. This is biology.

The 2025 research is still working its way into clinical practice. Most doctors are not yet prescribing based on vaginal microbiome composition at time of treatment. Most are not yet recommending biofilm-disrupting adjuncts alongside antibiotics as standard care.

But the research is there now. You can bring it to your appointments. You can ask the right questions. You are not imagining the pattern. The science now supports what you have been experiencing.

The Short Version

BV keeps coming back because Gardnerella vaginalis builds protective biofilms that standard antibiotic courses cannot penetrate or eliminate. And in women with a heavily dysbiotic microbiome, some of those bacteria are actually breaking down the antibiotics before they can do their job.

Three studies published in 2025, in npj Biofilms and Microbiomes, Communications Medicine, and Microorganisms, each add a piece to this picture. They collectively point toward the same conclusion: treating BV recurrence requires targeting the biofilm, not just the bacteria.

New approaches, including Bacillus spore probiotics, biofilm-disrupting compounds, and microbiome-aware treatment protocols, are showing promise in early research. None of these are widely available as standard care yet. But the direction of the science is clear, and it is moving fast.

If you have been stuck in the recurrence cycle, you are not stuck because of anything you are doing. You are stuck because the standard treatment tool is the wrong tool for the actual problem. Knowing this is the first step to getting out of the loop.